

Rajenahally S. Narasegowda,<sup>a</sup>  
 Hemmige S. Yathirajan<sup>a</sup> and  
 Michael Bolte<sup>b\*</sup>

<sup>a</sup>Department of Studies in Chemistry, University of Mysore, Manasagangothri, Mysore 570 006, India, and <sup>b</sup>Institut für Anorganische Chemie, J. W. Goethe-Universität Frankfurt, Marie-Curie-Straße 11, 60439 Frankfurt/Main, Germany

Correspondence e-mail:  
 bolte@chemie.uni-frankfurt.de

#### Key indicators

Single-crystal X-ray study  
 $T = 173$  K  
 Mean  $\sigma(\text{C}-\text{C}) = 0.002$  Å  
 $R$  factor = 0.022  
 $wR$  factor = 0.057  
 Data-to-parameter ratio = 14.2

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

## Nipecotic acid hydrochloride

The title compound (3-carboxypiperidinium chloride),  $\text{C}_6\text{H}_{12}\text{NO}_2^+\cdot\text{Cl}^-$ , is the hydrochloride of nipecotic acid and is used as a drug intermediate and in the synthesis of  $\gamma$ -aminobutyric acid (GABA) uptake inhibitors. The geometric parameters are in the normal ranges. The crystal packing is stabilized by  $\text{O}-\text{H}\cdots\text{Cl}$  and  $\text{N}-\text{H}\cdots\text{Cl}$  hydrogen bonds.


Received 10 February 2005

Accepted 17 February 2005

Online 26 February 2005

#### Comment

Nipecotic acid or 3-piperidinecarboxylic acid is used as a drug intermediate and also in the synthesis of  $\gamma$ -aminobutyric acid (GABA) uptake inhibitors (Muralidhar *et al.*, 1994). A review on the neurochemical and behavioural profile of a derivative of nipecotic acid hydrochloride has been reported by Suzdak & Jansen (1995). In view of the importance of nipecotic acid, the present paper reports the crystal structure of nipecotic acid hydrochloride, (I).



A perspective view of the title compound is shown in Fig. 1. Bond lengths and angles can be regarded as normal (Cambridge Structural Database, Version 1.7; Mogul Version 1.0.1; Allen, 2002). The heterocycle adopts a chair conformation. The crystal packing is stabilized by  $\text{O}-\text{H}\cdots\text{Cl}$  and  $\text{N}-\text{H}\cdots\text{Cl}$  hydrogen bonds.

#### Experimental

Nipecotic acid was purchased from the Aldrich Chemical Company and was converted to its hydrochloride by adding a mixture of isopropyl alcohol and hydrochloric acid (80/20). The compound was recrystallized from ethanol.

#### Crystal data

$\text{C}_6\text{H}_{12}\text{NO}_2^+\cdot\text{Cl}^-$   
 $M_r = 165.62$   
 Monoclinic,  $P2_1$   
 $a = 7.2545$  (10) Å  
 $b = 7.2018$  (9) Å  
 $c = 7.7886$  (13) Å  
 $\beta = 97.819$  (12)°  
 $V = 403.14$  (10) Å<sup>3</sup>  
 $Z = 2$

$D_x = 1.364$  Mg m<sup>-3</sup>  
 Mo  $K\alpha$  radiation  
 Cell parameters from 8363 reflections  
 $\theta = 3.8$ – $25.7$ °  
 $\mu = 0.42$  mm<sup>-1</sup>  
 $T = 173$  (2) K  
 Block, colourless  
 $0.37 \times 0.23 \times 0.19$  mm

Data collection

Stoe IPDS-II two-circle diffractometer  
 $\omega$  scans  
 Absorption correction: multi-scan (MULABS; Spek, 2003; Blessing, 1995)  
 $T_{\min} = 0.861$ ,  $T_{\max} = 0.925$   
 3354 measured reflections

1477 independent reflections  
 1460 reflections with  $I > 2\sigma(I)$   
 $R_{\text{int}} = 0.020$   
 $\theta_{\text{max}} = 25.5^\circ$   
 $h = -8 \rightarrow 8$   
 $k = -8 \rightarrow 8$   
 $l = -9 \rightarrow 9$

Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.022$   
 $wR(F^2) = 0.057$   
 $S = 1.10$   
 1477 reflections  
 104 parameters  
 H atoms treated by a mixture of independent and constrained refinement

$w = 1/[\sigma^2(F_o^2) + (0.0315P)^2 + 0.0946P]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\text{max}} < 0.001$   
 $\Delta\rho_{\text{max}} = 0.20 \text{ e } \text{Å}^{-3}$   
 $\Delta\rho_{\text{min}} = -0.17 \text{ e } \text{Å}^{-3}$   
 Extinction correction: SHELXL97  
 Extinction coefficient: 0.075 (10)  
 Absolute structure: Flack (1983), 671 Friedel pairs  
 Flack parameter: 0.10 (6)

Table 1

Selected geometric parameters (Å, °).

C2–N3	1.4972 (18)	C7–O2	1.187 (2)
N3–C4	1.502 (2)	C7–O1	1.323 (2)
C2–N3–C4	113.78 (12)	O2–C7–C1	123.39 (16)
O2–C7–O1	122.79 (15)	O1–C7–C1	113.68 (14)

Table 2

Hydrogen-bond geometry (Å, °).

$D-H \cdots A$	$D-H$	$H \cdots A$	$D \cdots A$	$D-H \cdots A$
O1–H1O $\cdots$ C11	0.89 (3)	2.11 (3)	2.9985 (13)	173 (2)
N3–H3A $\cdots$ C11 <sup>i</sup>	0.96 (2)	2.20 (2)	3.1428 (15)	166 (2)
N3–H3B $\cdots$ C11 <sup>ii</sup>	0.90 (2)	2.47 (2)	3.2525 (15)	147 (2)
N3–H3B $\cdots$ O2 <sup>ii</sup>	0.90 (2)	2.42 (2)	2.9590 (19)	119 (2)

Symmetry codes: (i)  $-x, y - \frac{1}{2}, -z + 1$ ; (ii)  $x, y, z - 1$ .

All H atoms were located in a difference map. Those bonded to C atoms were positioned geometrically and refined with fixed individual displacement parameters (set to 1.2 times  $U_{\text{eq}}$  of the parent C atom)




Figure 1

Perspective view of the title compound, showing the atom numbering and displacement ellipsoids drawn at the 50% probability level. The dashed line indicates a hydrogen bond.

using a riding model, with C–H = 0.99 and 1.0 Å for secondary and tertiary H atoms. The H atoms bonded to N and O atoms were refined freely. The ADDSYM routine in PLATON (Spek, 2003) detects a pseudo-centre of symmetry in the structure, which is fulfilled by approximately 80% of the structure. This would mean changing the space group from  $P2_1$  to  $P2_1/m$ . In this case, the molecule must lie on a mirror plane. However, the molecule does not have any symmetry at all. Therefore,  $P2_1$  is the correct space group and it is just a pseudo-centre of symmetry that PLATON detects.

Data collection: X-AREA (Stoe & Cie, 2001); cell refinement: X-AREA; data reduction: X-AREA; program(s) used to solve structure: SHELXS97 (Sheldrick, 1990); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: PLATON (Spek, 2003); software used to prepare material for publication: SHELXL97 and PLATON.

References

Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.  
 Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.  
 Flack, H. D. (1983). *Acta Cryst.* **A39**, 876–881.  
 Muralidhar, T. G., Borden, L. A., Tyagarajan, S., Smith, K. E., Branchek, T. A., Weinshank, R. L. & Gluchowski, C. (1994). *J. Med. Chem.* **37**, 2334–2342.  
 Sheldrick, G. M. (1990). *Acta Cryst.* **A46**, 467–473.  
 Sheldrick, G. M. (1997). SHELXL97. University of Göttingen, Germany.  
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.  
 Stoe & Cie (2001). X-AREA. Stoe & Cie, Darmstadt, Germany.  
 Suzdak, P. D. & Jansen, J. A. (1995). *Epilepsia*, **36**, 612–626.